Dr Reddy's Q3 2026 earnings show steady growth
after close1 source ↓written by the desknot a recommendation
- reflecting
- 4.4% YoY growth
- excluding a one-time
- 24.8%
Dr Reddy's Laboratories reported Q3 2026 revenue of ₹8,727 cr, reflecting a 4.4% YoY growth. The EBITDA margin was 23.5%, adjusted to 24.8% excluding a one-time provision. Despite a 16% decline in North America Generics revenue, the company maintained a net cash surplus of ₹3,069 cr. This performance may bolster investor sentiment in the pharma sector.
• Profit After Tax: ₹1,210 cr
• Diluted EPS: ₹14.52
• Free Cash Flow: ₹374 cr
Not investment advice. For informational purposes only.